Originally published May 5, 2018
The original blog below appears to be unique in pursuing testosterone levels in prostate tissue (measured in biopsy specimens). Since then, however, a research team out of Verona, Italy has published several articles linking aggressive prostate cancer (PCa) with a factor called endogenous testosterone density (EDT).
EDT is calculated as the ratio between circulating testosterone and prostate volume. The larger the prostate, the lower the density number; and the lower the density, the more it predicts aggressive PCa[i]. Low EDT also predicts lymph node involvement[ii]. On the other hand, a high EDT correlates with larger tumors[iii].
One other article of note, this one out of Fukuoka, Japan, examined testosterone levels in seminal vesicle fluid. The authors found that high testosterone concentrations in the fluid correlated with PCa incidence. Add these findings to the study reported in the blog below for more pieces of the jigsaw puzzle of testosterone and PCa.
The PSA/biopsy puzzle
Did you ever work on a 1,000 piece jigsaw puzzle? If so, you probably found yourself in a situation where one section has come together nicely, but a piece is still missing. 600 loose pieces are lying all around the unfinished puzzle on the table. You know EXACTLY what the missing piece should look like, and you have scanned over those 600 pieces at least 10 or 12 times, but you are looking for is not to be found. It’s maddening, so you move to another area of the puzzle and start working there. Several hours later (in jigsaw puzzle time) you stumble on the previously missing piece. It doesn’t look like what you were expecting, but somehow you now recognize it instantly. Aha! Triumphantly, you put it where it goes and you think, “It was right there in front of me all the time. How come I didn’t see it sooner?
A big prostate cancer puzzle is the search for a reliable, inexpensive way to know if a newly diagnosed prostate cancer (PCa) patient is harboring a dangerously aggressive tumor. Of course, his clinical factors (age, PSA, Gleason score and tumor stage) provide significant information. But maybe there’s a puzzle piece lying right in front of us, but we don’t recognize it because it doesn’t look like what we are picturing in our heads.
Looking for testosterone in a biopsy needle
A Japanese research team may have found a missing piece of the big picture.[iv] Their starting point was the fact that there was no consensus on a possible connection between testosterone levels in the prostate gland itself, and the aggressiveness of prostate cancer. But there hasn’t been a good way to measure testosterone in prostate tissue.
Generally, testosterone is measured by a blood draw to evaluate the amount of this male hormone circulating in the blood. Until the work of this team, there wasn’t really an accurate or efficient way to measure testosterone in the very small tissue samples that are obtained using biopsy needles. Previous efforts to measure androgen levels in tissue using radioimmunoassay had problems. Not only were large tissue specimens needed (e.g. prostatectomy specimens) but there were concerns with tissue-handling issues, confounding factors, and problems with methodological accuracy.[v] However, due to advances in a chemical analysis technology called liquid-chromatography tandem mass spectrometry (LC-MS/MS), the team was able to overcome the challenge of reliably and specifically assessing testosterone levels in a very small thread of prostate tissue from a biopsy.
For the study, the researchers used blood and biopsy samples from 196 patients diagnosed with PCa. What they found was that clinical factors such as high Gleason score and percent of positive biopsy needles were strongly correlated with high concentrations of testosterone in the prostate gland. The hormone concentration was consistently high throughout the gland, whether in healthy tissue or tumor tissue.
Thus, at the time of biopsy, if there are high androgen (male hormone) concentrations in the prostate tissue “snips” as well as PCa cells, it would indicate a need for aggressive treatment since such patients would be at risk for advanced PCa. The authors conclude, “Tissues T levels determined from biopsy specimens, in combination with pathological features, may be one of several useful diagnostic tools for predicting the prognosis and determining a suitable therapeutic program for patients with prostate cancer.”[vi]
How did all that testosterone get there?
This leads us to a different section of the puzzle: what is all that testosterone doing there, and how is it connected with PCa? One recent theory as presented in a 2009 paper by Gat et al.[vii] suggests that free testosterone – the kind most readily available to be taken up by prostate cells – gets saturated in the prostate gland due to a plumbing problem (backflow of blood containing free testosterone into the prostate). I have previously written about that theory. At that time I wrote:
According to Gat’s publication, when the abnormal valves lead to a concentration of free testosterone in the prostate, this hormone places constant stress on the genes that respond to it. (Remember: hormones are chemical messengers.) This stress pushes cell mutations, as an increasing number of genetic errors occur – and the cell’s mechanism for detecting copy errors is increasingly damaged. The authors theorize that rapid proliferation of prostate cells results, leading to the condition known as benign prostatic hyperplasia (BPH), and eventually to prostate cancer in many cases.
If you are interested, you may want to get caught up by reading my blog post on the subject.
For now, I believe that the Japanese study is the piece that completes the section of the prostate puzzle on the true relationship between testosterone and prostate cancer. It indirectly supports the Gat hypothesis that high male hormone concentrations trapped in the prostate gland eventually cause trouble.
Gat’s work is out there for all to see, but perhaps it is being overlooked because it’s not the answer science imagines it’s looking for.
NOTE: This content is solely for purposes of information and does not substitute for diagnostic or medical advice. Talk to your doctor if you are experiencing pelvic pain, or have any other health concerns or questions of a personal medical nature.
References
[i] Porcaro AB, Gallina S, Bianchi A, Cerrato C et al. Endogenous testosterone density as ratio of endogenous testosterone levels on prostate volume predicts tumor upgrading in low-risk prostate cancer. Int Urol Nephrol. 2021 Dec;53(12):2505-2515.
[ii] Porcaro AB, Tafuri A, Panunzio A, Mazzucato G et al. Endogenous testosterone density is an independent predictor of pelvic lymph node invasion in high-risk prostate cancer: results in 201 consecutive patients treated with radical prostatectomy and extended pelvic lymph node dissection. Int Urol Nephrol. 2022 Mar;54(3):541-550.
[iii] Porcaro AB, Panunzio A, Tafuri A, Cerrato C et al. The Influence of Endogenous Testosterone Density on Unfavorable Disease and Tumor Load at Final Pathology in Intermediate-Risk Prostate Cancer: Results in 338 Patients Treated with Radical Prostatectomy and Extended Pelvic Lymph Node Dissection. Urol Int. 2022;106(9):928-939.
[iv] Miyoshi Y, Uemura H, Umemoto S, Sakamaki K et al. High testosterone levels in prostate tissue obtained by needle biopsy correlate with poor-prognosis factors in prostate cancer patients. BMC Cancer. 2014; 14: 717. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190297/
[v] Ibid.
[vi] Ibid.
[vii] Gat Y, Joshua S, Gornish MG. Prostate cancer: a newly discovered route for testosterone to reach the prostate : Treatment by super-selective intraprostatic androgen deprivation. Andrologia. 2009 Oct;41(5):305-15. Andrologia.
About Dr. Dan Sperling
Dan Sperling, MD, DABR, is a board certified radiologist who is globally recognized as a leader in multiparametric MRI for the detection and diagnosis of a range of disease conditions. As Medical Director of the Sperling Prostate Center, Sperling Medical Group and Sperling Neurosurgery Associates, he and his team are on the leading edge of significant change in medical practice. He is the co-author of the new patient book Redefining Prostate Cancer, and is a contributing author on over 25 published studies. For more information, contact the Sperling Prostate Center.
